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Summary. Background: Procoagulant platelets comprise a phenotypically distinct subpopulation of activated platelets with high-level phosphatidylserine externalization. When initiated by co-stimulation with thrombin and a glycoprotein VI (GPVI) agonist, the transition to the procoagulant phenotype is mediated by extracellular calcium entry and mitochondrial permeability transition pore (mPTP) formation. Objectives: The intracellular mechanisms coordinating these distinct cytoplasmic and mitochondrial processes remain unclear. The mitochondrial calcium uniporter (MCU) protein is a central component of the transmembrane ion channel that allows the passage of Ca 2+ from the cytosol into the mitochondrial matrix. Here we investigate the role of the MCU in the regulation of procoagulant platelet formation. Results: Procoagulant platelet formation was directly correlated with pre-stimulatory mitochondrial transmembrane potential, a key determinant of calcium flux from the cytoplasm to the mitochondria. The role of MCU in the regulation of procoagulant platelet formation was investigated using MCU null platelets. Procoagulant platelet formation in MCU null platelets was significantly decreased coincident with decreased mPTP formation. In contrast, neither granule release nor initial integrin activation was altered in response to stimulation. In the genomic absence of MCU, developmental induction of an alternative intracellular pathway partially rescued procoagulant platelet formation. Conclusion: These results identify a key role for the mitochondrial calcium uptake channel in the regulation of mPTP-mediated procoagulant platelet formation and suggest a novel pharmacologic target for procoagulantplatelet-related pathologies.
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Introduction
Co-stimulation of platelets with the strong agonists, thrombin and collagen, results in the formation of a phenotypically and functionally distinct subpopulation of activated platelets referred to as the procoagulant platelets [1, 2] . Among the procoagulant platelets' unique features are the exposure of high levels of phosphatidylserine (PSer) on the platelet surface and decreased aggregatory and adhesive properties [3] [4] [5] . As a major contributor of a PSer surface for the assembly of the tenase and prothrombinase complexes, procoagulant platelets function as a nexus for the initiation of coagulation within hemostatic thrombi [6, 7] .
In the absence of cyclophilin D (CypD) activity and the consequent impairment of mitochondrial permeability transition pore (mPTP) formation, procoagulant platelet formation is markedly blunted [8, 9] . This defect in platelet function is limited to the distinctive characteristics of the procoagulant platelet, as neither granule release nor initial integrin activation is affected by the absence of CypD activity [8] . A primary molecular role of the mitochondrial matrix protein CypD is the potentiation of calcium-mediated mPTP formation [10] . Sustained elevation of the cytoplasmic calcium concentration occurs in strongly stimulated platelets and is required for procoagulant platelet formation [11, 12] .
Pharmacologic studies suggest that elevation of the calcium concentration within the mitochondrial matrix is an essential trigger for mPTP and procoagulant platelet formation [13] .
The molecular identity of the key pathway mediating calcium entry from the cytoplasm and through the inner mitochondrial membrane has only recently been identified [14, 15] . A mitochondrial calcium uniporter (MCU) protein oligomer functions as the central channel of a mitochondrial calcium channel complex. In MCU's absence rapid calcium entry is almost completely eliminated. Surprisingly, despite the long-accepted role of mitochondrial calcium elevation in mediating ischemic and calcium-overload mediated cell death, genomic absence of MCU has no effect on cell death in nucleated cells [16] . Whether mitochondrial calcium entry (upon activation by co-stimulation of protease activated receptor (PAR) and glycoprotein VI (GPVI)) mediated by MCU plays a role in procoagulant platelet formation is unknown. Here, utilizing MCU knockout (MCU À/À ) platelets, we demonstrate an essential role for MCU in the regulation of the mPTPdependent procoagulant platelet formation and, unique among cell types thus far examined, identify the dependence of this cell death-like process on the genomic presence of the MCU protein.
Materials and methods
All human blood samples were donated as approved by the institutional review board of the BloodCenter of Wisconsin, and informed consent was obtained in accordance with the Declaration of Helsinki. Mice were housed in pathogen-free conditions under the supervision of the Biomedical Resource Center at the Medical College of Wisconsin. C57BL/6 mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). MCU À/À mice were generated in Dr. Toren Finkel's laboratory and obtained from the Texas A&M Institute for Genomic Medicine. Age-and sex-matched mice were used for each experiment. Murine blood was collected into acid citrate dextrose as anticoagulant. Human blood was collected into citrate. Washed platelets were isolated as described previously, and resuspended in Tyrode's buffer for 30 min at room temperature before experiments [17] .
Washed platelets in Tyrode's buffer with CaCl 2 (2.1 mM) were stimulated with agonist(s) as indicated. For experiments evaluating loss of mitochondrial membrane potential (Dwm) platelets were incubated with 500 nM tetramethylrhodamine methyl ester (TMRM). Labeled platelets were evaluated by flow cytometry at 37°C. For aggregation studies, washed platelets were pretreated with either dimethyl sulfoxide (DMSO) or ruthenium 360 (Ru360) and then stimulated with protease-activated receptor 1 (PAR1) peptide or collagenrelated peptide (CRP). Change in light transmission was recorded by a chrono-log aggregometer.
Washed platelets (1 9 10 9 /mL) suspended in Tyrode's buffer containing 2.1 mM CaCl 2 were incubated with thrombin and convulxin for 7 min at 37°C. Platelets were then stained with anti-CD41 antibodies and annexin V for 1 min and fixed with 1% paraformaldehyde. Platelets were allowed to settle by gravity sedimentation (overnight at 4°C in the dark). Fluorescence and platelet morphology were visualized using Olympus Fluoview FV1000 (Olympus Corporation of the Americas, Center Valley, PA, USA). Images were recorded for off-line analysis.
Results are presented as mean AE SEM. The statistical significance between groups was determined by Student's t-test or one-way ANOVA. Sample size is equal to or more than 4.
Results and Discussion
Although a molecular mechanism of calcium ion entry is essential, the primary driver of calcium influx from the cytoplasm to the mitochondrial matrix is the electrochemical potential across the inner mitochondrial membrane (mitochondrial membrane potential or DΨ m ), which is primarily generated by the proton motive force of the electron transport chain [18] . Consistent with a central role for mitochondrial calcium influx in the regulation of procoagulant platelet formation, depolarization of the mitochondrial membrane using either the complex I inhibitor rotenone or the protonophore Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone significantly decreased procoagulant platelet formation (Fig. 1A) . Conversely, an increase in pre-stimulatory DΨ m , using either antimycin A or oligomycin, increased procoagulant platelet formation as much as 2-fold. Interestingly, regression analysis evaluating the effects of these pharmacologic modulators revealed an almost linear correlation between pre-stimulatory DΨ m and subsequent agonist-induced procoagulant platelet formation.
MCU functions as the primary molecular component of the MCU protein complex. Genomic MCU deletion eliminates rapid mitochondrial calcium influx (17) . The close similarities between nucleated cell death, particularly necrosis, and procoagulant platelet formation, together with the significant experimental data demonstrating a role for mitochondrial calcium influx in platelets (Fig. 1A and [19] ), led us to investigate the effects of genomic MCU deletion on platelet function. Evaluation of the complete blood count in MCU À/À and MCU +/+ mice (Fig. 1B) revealed no difference in platelet count. As previously reported, significant embryonic lethality [16] was noted upon deletion of both MCU copies (heterozygote-crossed generation of MCU nulls was 8% and gradually decreased to 0% within four to five generations), limiting animal numbers for subsequent analyses. Platelet activation was investigated in murine platelets using flow cytometry. Alone, neither thrombin nor the GPVI agonist convulxin caused a significant increase in PSer exposure (Fig. 2A) . Co-stimulation with thrombin (THR) and the GPVI agonist convulxin (CVX) (THR/ CVX) resulted in high-level PSer exposure in the majority of MCU +/+ platelets ( Fig. 2A) . Absence of MCU decreased dual-agonist-mediated PSer externalization bỹ 55% relative to MCU +/+ . In wild-type platelets, platelet PSer exposure induced by THR/CVX is almost completely blunted in the absence of CypD activity (1, 9, 23) . In contrast to the effects of CypD inhibition on wild-type platelets, inhibition of CypD activity (1 lM CsA, Fig. 2B ) had no effect on the residual PSer exposure observed following THR/CVX stimulation of MCU À/À platelets.
Bypassing the effect of MCU deletion with Ca 2+ ionophore (100 lM ionomycin) revealed no difference in PSer exposure between MCU genotypes (Fig. 2C) , indicating that Ca 2+ -induced programmed necrosis is not altered in MCU À/À platelets. Together, these results suggest that, in the setting of a genomic absence of MCU, compensatory pathways alternative to those mediated through the MCU and mPTP formation emerge to mediate procoagulant platelet formation. However, the similar sensitivity of wild-type (WT) and MCU À/À platelets to the BH3 mimetic ABT-737 argues against the emergence of a BH-3 apoptotic pathway (Fig. 2C) . Additional aspects of procoagulant platelets were similarly altered in the absence of MCU. Closure, or secondary inactivation, of integrin a IIb b 3 [4, 20] (Fig. 2D ). There was also no difference in granule release between experimental groups as measured by surface exposure of the alpha granule protein P-selectin (Fig. 2E) . Loss of the cationic fluorophore TMRM occurs coincident with the procoagulant platelet transition as a result of mPTP formation and loss of DΨ m (9) . As with the effects of MCU's absence on phosphatidylserine externalization, mPTP formation, as assessed by loss of TMRM, was similarly impaired in MCU À/À platelets following dual-agonist stimulation (Fig. 2F) . Importantly, pre-stimulatory or baseline DΨ m , as assessed by TMRM, was unaffected by MCU's absence, demonstrating the integrity of this aspect of mitochondrial function. To further demonstrate that the defect in platelet function occurring as a result of MCU inhibition or ablation is limited to procoagulant platelet formation, platelet aggregation was investigated in human platelets using the pharmacologic inhibitor Ru360. No difference in either PAR1 peptide (Fig. 3A) or CRP (Fig. 3B ) simulated platelet aggregation was noted in MCU WT versus MCU À/À platelets. Thus, these findings demonstrate a key role for the MCU complex in the physiologic initiation of procoagulant platelet formation and demonstrate the upstream role of regulated Ca 2+ entry into the mitochondrial matrix in both agonist-regulated mPTP formation and procoagulant platelet formation.
Morphologically, procoagulant platelets have two readily recognizable components [6, 21] . Rapid platelet expansion rendered through the process of osmotic swelling results in the formation of a platelet 'balloon' with a discrete 'cap' that consists of remnants of the vast majority of platelet organelles. The cap contains the area of greatest PSer exposure and coagulation enzyme complex assembly [6] . Remarkably, our flow cytometry studies indicate (Fig. 2 ) that an alternative non-mPTP-driven mechanism mediates procoagulant platelet formation in the genomic absence of MCU. Thus, the effect of MCU's absence on procoagulant platelet morphology was more closely investigated using confocal microscopy. As expected from the flow cytometry studies, the percentage of annexin V-positive (PSer exposing) platelets formed following agonist stimulation was significantly lower in MCU null mice (not shown). However, among these remnant MCU null and PSer externalizing platelets no difference in morphology was noted from that seen in WT (Fig. 3C and D) . Both MCU WT (mPTP dependent) and MCU null procoagulant platelets demonstrated the characteristic cap and balloon as assessed by co-localization of CD41 and annexin V [6] .
Both sustained cytoplasmic calcium elevation and mPTP formation are essential for procoagulant platelet formation, but how these two disparate events are coordinated has been contested. By provoking a loss of calcium buffering capacity by the mitochondria, mPTP formation has been suggested to elevate cytosolic calcium levels, which is required for phospholipid scrambling and calpain-mediated integrin deactivation [20, 22] . Alternatively, we have also recently proposed that sustained cytosolic calcium elevations that occur as a result of dual-agonist stimulation result in calcium entry into the mitochondria, mPTP formation, and then procoagulant platelet formation [19] . Here, by demonstrating the key role of MCU and its mechanism of action upstream of mPTP formation, we provide additional evidence that this second mechanism predominantly regulates the physiologic formation of procoagulant platelets (Fig. 4) . However, in the genomic absence of MCU, sustained cytosolic calcium elevation in the absence of the calcium buffering capacity of the MCU may be sufficient to drive the residual procoagulant platelet formation that is observed. In platelets, distinct from cardiomyocytes, absence of MCU markedly impacted the initiation of a cell death process, namely programmed necrosis (16) . This result is consistent with the known relative importance of calcium and mPTPdependent mechanisms, as opposed to apoptosomemediated events, in procoagulant platelet formation [8, 23] . Even so, in MCU's absence, long-term compensatory mechanisms result in adaptation and utilization of alternative mechanisms of cell death in platelets, as observed in other cell types. It is tempting to propose that the alternative molecular mechanism of PSer externalization present in MCU null platelets is identical to the TMEM-16F-, mPTP-and caspase-independent mechanism of PSer externalization observed in thrombin and collagen-stimulated platelets [24] . Further studies are needed to determine the identity of the alternative cell death pathway(s), which are shown here to emerge in the absence of MCU.
In strongly stimulating environments a procoagulant response is evoked in a subpopulation of platelets [25] . Inhibition of cytoplasmic calcium elevation, such as by abrogation of store-operated calcium entry, blocks procoagulant platelet formation, but also inhibits multiple aspects of platelet activation, including platelet adhesion and aggregation. Pathologic roles for the procoagulant platelet have been proposed in thrombotic and inflammatory conditions [25] [26] [27] . The results presented here indicate that specific pharmacologic inhibition of the MCU complex and mitochondrial calcium entry might effectively abrogate procoagulant platelet formation without affecting other aspects of platelet activation. Thus, these results identify the MCU complex as a novel pharmacologic target specific to the prevention of procoagulant-platelet-related pathologies without affecting normal hemostasis.
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